Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Abstract Background Epoprostenol AS (Veletri®), a thermostable epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri®, especially regarding tolerability, s...

Full description

Bibliographic Details
Main Authors: Julia Degering, Benjamin Egenlauf, Satenik Harutyunova, Nicola Benjamin, Amina Salkić, Panagiota Xanthouli, Christina A. Eichstaedt, Rebekka Seeger, Olivier Sitbon, Ekkehard Grünig
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Respiratory Research
Subjects:
Epoprostenol
Pulmonary hypertension
Veletri
Online Access:https://doi.org/10.1186/s12931-022-02296-z

Internet

https://doi.org/10.1186/s12931-022-02296-z

Similar Items